Tesamorelin

Tesamorelin is a stabilized, synthetic 44-amino acid analogue of GHRH that possesses a unique lipophilic domain, granting it a significantly extended half-life and enhanced stability compared to native GHRH. Its mechanism involves potent stimulation of the GH/IGF-1 axis, specifically targeting the reduction of visceral adipose tissue (VAT) through the promotion of lipolysis and inhibition of adipocyte differentiation. Research has demonstrated its remarkable efficacy in reducing trunk fat mass without affecting subcutaneous fat, making it a prime subject for HIV-associated lipodystrophy and central obesity studies. Beyond metabolic effects, Tesamorelin is researched for its neuroprotective qualities, particularly in mild cognitive impairment, due to the neurotrophic effects of the GH surge it induces. It has received extensive clinical validation, and researchers utilize it to study selective fat reduction pathways, hepatic glucose output modulation, and cognitive preservation in aging populations.